Sichuan Kelun-Biotech Biopharmaceutical revenue and financials

6990 · HKEX · HKD

Compare Sichuan Kelun-Biotech Biopharmaceutical
$398.40Change from previous close: −5.59%Absolute change: −$23.60

Close · November 20, 2026

In the fiscal year ended December 2025, Sichuan Kelun-Biotech Biopharmaceutical reported revenue of ¥2.06B (+6.46% year over year). The net loss was ¥381.97M.

Annual revenue · 2025: ¥2.06B
  1. ¥32.32M2021
  2. ¥803.93M2022
  3. ¥1.54B2023
  4. ¥1.93B2024
  5. ¥2.06B2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+6.46%
2025 vs 2024
Net margin
-18.6%
2024: -13.8%

How Sichuan Kelun-Biotech Biopharmaceutical is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of CNY; per-share values in CNY; shares in millions.

Income statement · Annual
Item20252024202320222021
Total revenue2,0581,9331,54080432.3
Cost of revenue57965978127723.1
Gross profit1,4791,2747595279.3
Selling, general and administrative65434620193.091.0
Research and development1,3201,2061,031846728
Operating income-420-279-454-394-795
EBIT-420-279-454-394-795
EBITDA-365-231-420-368-776
Interest expense6.23.884.3149113
Pre-tax income-356-143-468-567-890
Income tax26.212410648.7—
Net income-382-267-574-616-890
Net income to common shareholders-382-267-522-548-823
Basic EPS-1.66-1.20-2.84-5.74-8.90
Diluted EPS-1.66-1.20-2.84-5.74-8.90
Average shares (basic)23122218495.592.5
Average shares (diluted)23122218495.592.5

Companies in the group: same industry, similar size